1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd

BBSE:NOVELIX
61.00
INR
-1.73
(-2.76%)
1.89EPS
40.58P/E
1.83BMarket Cap
Novelix Pharmaceuticals Ltd
BSE:NOVELIX
(Bombay Stock Exchange)

Recent

price

61.00

P/E

ratio

40.58

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
24.47
17.32
7.35
7.12
7.84
7.06
11.34
12.97
12.2
12.65
11.41
1.04
1.73
4.06
30.87
62.75
76.3
Revenue per Share
0.7
0.69
0.47
0.53
0.11
0.12
-0.01
-0.43
-0.18
-0.32
-4.65
-1.93
-0.07
0.01
0.08
1.21
1.89
Basic EPS, GAAP
-0.95
-0.53
-4.45
-0.34
0.24
1.86
-3.82
- -
-0.83
0.64
1.93
-1.57
-2.97
-0.33
-13.86
-12.16
- -
Free Cash Flow per Basic Share
- -
0.3
0.25
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
11.65
11.99
13.62
14.16
14.11
14.26
14.23
13.79
13.48
13.09
8.47
8.6
8.88
9.08
17.63
22.05
- -
Book Value per Share
10.16
10.8
12.88
13.62
13.83
14.22
14.21
13.77
13.45
13.02
8.43
8.6
8.88
9.08
17.63
21.13
- -
Tangible Book Value per Share
7
7
8
8
8
8
8
8
8
8
8
8
8
10
10
21
19
Basic Weighted Avg Shares
165
117
60
58
63
57
92
105
99
102
92
8
14
42
307
1,323
1,469
Sales/Revenue/Turnover
1.05
4.05
9.39
10.88
6.95
4.53
0.85
-1.56
-9.54
-6.73
-11.26
-69.88
-40.86
-3.09
1.4
2.63
3.02
Operating Margin (%)
3
3
3
3
4
4
2
2
2
2
2
1
1
- -
- -
1
2
Depreciation Expense
5
5
4
4
1
1
- -
-3
-1
-3
-38
-16
-1
- -
1
26
36
Net Income, GAAP
32.09
23.31
31.04
31.73
47.71
46.37
82.75
- -
- -
- -
- -
- -
- -
51.02
31.47
24.9
16.59
Effective Tax Rate (%)
2.86
3.97
6.34
7.4
1.34
1.73
-0.12
-3.32
-1.5
-2.53
-40.73
-185.05
-4.27
0.25
0.28
1.93
2.47
Profit Margin (%)
57
61
96
104
96
108
102
96
97
96
52
46
42
41
173
430
- -
Working Capital
1
- -
- -
- -
- -
- -
10
10
9
8
- -
1
- -
- -
- -
43
- -
LT Debt
79
81
110
117
117
121
119
116
114
111
74
72
72
74
175
465
- -
Total Equity
5.98
5.76
3.88
3.73
1.19
1.08
0.27
- -
- -
- -
- -
- -
- -
-1.92
0.58
7.45
- -
Return on Invested Capital (%)
5.98
5.85
3.97
3.71
0.26
0.58
-0.39
- -
- -
- -
- -
- -
- -
0.15
0.68
7.53
- -
Return on Capital (%)
6.1
5.82
3.95
3.79
0.74
0.86
-0.1
-3.07
-1.34
-2.41
-43.09
-22.56
-0.85
0.14
0.68
7.99
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
43
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
21
24
Market Capitalization
1,078
1,176
1,828

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
889
- -
Cash, Cash Equivalents & STI
- -
30
- -
Accounts Receivable, Net
- -
590
- -
Inventories
- -
144
- -
Total Current Liabilities
- -
459
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.17%
60.69%
165.05%
Free Cash Flow
-2,251.82%
764.64%
85.96%
Net Income, GAAP
769.6%
673.01%
2,925.56%
Sales/Revenue/Turnover
119.74%
226.88%
330.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
6
40
53
209
307
2026
224
364
484
252
1,323
2027
369
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.43
0.16
0.15
0.18
0.08
2026
0.09
0.37
0.58
0.43
1.21
2027
0.49
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Trimurthi Limited is an Indian pharmaceutical company primarily engaged in the manufacturing and marketing of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Its core products include pharmaceutical tablets; oral liquids; capsules; injections; ointments; syrups; and bulk drug intermediates. The company serves various therapeutic segments such as antibiotics, analgesics, anti-inflammatory drugs, and vitamins, catering to domestic and international markets. Established in 1974, Trimurthi Limited is headquartered in Hyderabad, India. Recently, Trimurthi Limited has focused on strategic expansions and product portfolio enhancements to strengthen its market position. In the last one to two years, the company has pursued business expansions through new product launches aimed at broadening its therapeutic offerings and enhancing export capabilities. It continues to develop partnerships and alliances to boost its research and development efforts and operational scale. These steps align with its goal to enhance competitiveness and presence in both the domestic Indian pharmaceutical market and export destinations. Trimurthi Limited operates broadly within the pharmaceutical industry, targeting hospitals, healthcare providers, pharmacies, and distribution networks across India and select overseas markets. Its operations encompass drug formulation manufacturing, contract manufacturing services, and active pharmaceutical ingredient production. The company maintains compliance with regulatory standards and seeks to innovate in pharmaceutical solutions to meet the evolving healthcare demands globally. Trimurthi Limited remains a significant player in the pharmaceutical sector with a comprehensive product range and an ongoing commitment to growth and innovation.